36.6 F
New York
Thursday, April 22, 2021

Gilead Sciences [NASDAQ: GILD] To Start Testing Of Inhalable Version Of Remdesivir For COVID-19

Must read

Palantir [NYSE: PLTR] Recognized as a Crown Commercial Service supplier

Palantir Technologies Inc. has gained recognition as a supplier on the Crown Commercial Service (CCS) Back Office Software (BOS) RM6194 Framework. This award...

Trevena [NASDAQ: TRVN] Soar on Selection of TRV027in Global COVID-19 Trial

Shares of Trevena, Inc. skyrocketed more than 5 percent during the pre-market trading session of Wednesday. The strong performance of the firm indicated...

InfuSystem Announces Acquisition of OB Healthcare Corporation

InfuSystem Holdings Inc. disclosed Wednesday that it has bought OB Healthcare Corporation. As per the acquisition agreement, the firm has purchased the operating...

IAA [NYSE: IAA] Announces Expansion of Delivery Services in the UK

IAA, Inc. disclosed that its UK-based business unit has decided to expand its vehicle delivery services for its buyers. This expansion decision has...

Gilead Sciences, Inc. [NASDAQ: GILD] has started the human testing of the inhaled version of coronavirus drug remdesivir. The company aimed to make the treatment possible which not involve hospitalization.

FDA has given an emergency authorization to Gilead Sciences, Inc. for the use of investigational drug remdesivir for the treatment of COVID-19 in May. According to the company, the testing for the inhaled version of remdesivir will enroll 60 healthy Americans between the age of 18 and 45. Gilead Sciences will test the drug only on those patients who have the disease but not progressed to the point where they need hospitalization.

Remdesivir is the antiviral drug that is being studied in multiple phases. In the current health emergency, the approval for this drug varied in countries. In the countries, where remdesivir is not approved by the authorities it is used as an investigational drug and its efficacy and safety have not been confirmed yet.

Shares of Gilead, Sciences, Inc. [GILD] plummeted 1.06% in the trading on Wednesday after it announced the phase 1a testing of the inhaled version of remdesivir. This company had a trading volume of 6.2 million as compared to the average volume of 16.44 million.

Gilead Sciences, Inc. has a Gross Margin of 79.40%, a Profit Margin of 21.80%, and an Operating Margin of 19.60%. GILD’s return on assets, equity and investment is 8.10%, 22.60%, and 9.50%, respectively.

More articles

Latest article

ICON [NASDAQ: ICLR] Secures Multiple Categories in 2021 CRO Leadership Awards

ICON Public Limited Company has disclosed that it has won multiple categories in the annual CRO Leadership Awards. This is another greatest achievement...

Equinox Announces Sale of Pilar Gold Mine

Equinox Gold Corp. revealed Monday that it has decided to sell its Pilar Gold Mine in Brazil to Pilar Gold Inc. The firm...

OpGen [NASDAQ: OPGN] Announces Strategic Collaboration New York State Department of Health

OpGen, Inc. revealed that it has entered into a strategic collaboration deal with the New York State Department of Health. The focus of...

Why Mer Telemanagement [NASDAQ: MTSL] Skyrocketed on Friday?

Shares of Mer Telemanagement Solutions Ltd skyrocketed during the trading session of Friday. The strong performance of the firm has indicated the positive...

Largo Resources Gets Approval for Listing on Nasdaq Stock Exchange

Largo Resources disclosed that it has finally obtained authorization from Nasdaq Stock Market LLC. As per the approval, the firm will now eligible to...

Aurora Mobile [NASDAQ: JG] Inks Agreement with Wanda Film

Aurora Mobile Limited disclosed Thursday that it has inked an agreement with Wanda Film Holding Co Ltd. Since its inception, Aurora Mobile has...

Brady [NYSE: BRC] Commence Tender Offer to Buy Nordic ID Oyj

Brady Corporation has inked an agreement with Nordic ID for its acquisition. The firm has commenced the tender offering to buy all the...

Cinedigm [NASDAQ: CIDM] Achieve Record Subscription and Ad-Supported User Growth Milestones

Shares of Cinedigm Corp. skyrocketed 19.30% after the firm reported the update about the subscription. The firm has achieved the best ever achievement...